Rozanolixizumab
id:
rozanolixizumab-183-9365310
title:
Rozanolixizumab
text:
Rozanolixizumab, sold under the brand name Rystiggo, is a monoclonal antibody used for the treatment of myasthenia gravis. Rozanolixizumab is a humanized and chimeric monoclonal antibody; and is a neonatal Fc receptor blocker. The most common adverse reactions include headache, infections, diarrhea, pyrexia, hypersensitivity reactions, and nausea. Rozanolixizumab was approved for medical use in the United States in June 2023, and in the European Union in January 2024.
brand slug:
wiki
category slug:
encyclopedia
description:
Monoclonal antibody medication
original url:
https://en.wikipedia.org/wiki/Rozanolixizumab
date created:
2023-06-29T04:08:53Z
date modified:
2024-09-07T04:31:29Z
main entity:
{"identifier":"Q120491843","url":"https://www.wikidata.org/entity/Q120491843"}
image:
fields total:
13
integrity:
15